May 22, 2020 | By Louis Loeb
A new spring and almost summer are above our office at Biogenity, reminding us that after autumn storms and the cold of winter comes the sun, warmth and the beautiful sight of flowering nature. COVID-19 has a huge and terrible impact on the world and show how vulnerable we still are to viruses.
The impact of COVID-19 did hit Biogenity. However, due to the great support received from Horizon 2020 and the Innovation Fund Denmark for our research and development projects, the impact wasn't significant. It reminded us why Biogenity was founded almost two years ago, the vision of being a catalyst in drug discovery and a mission of contributing to the healthcare system.
A lot has changed in the two years, yet the mission stays the same. That is why we are ready with a new website, new products, new collaborations, and new developments, all aimed to catalyse research and discovery, enabling rapid development of diagnostic and treatment tools.
Before giving a brief introduction to the new development and the new product, we want to acknowledge two of our collaborators; YUMAB GmbH and Abcalis GmbH. YUMAB and partners have developed promising SARS-CoV-2 antibody candidates for treatment, and Abcalis provide anti-SARS-CoV-2 antibodies for diagnostics.
Rapid quality antibody development is essential in time like these, which is why we are proud to tell that we are in the last stage of development of an AI software that catalyses exactly this.
By using Biogenity's antibody prediction software, you can achieve unprecedented precision when selecting your candidates for production. The software is developed specifically for identifying the candidates, who will give the best yield and be the most stable, designed to provide answers that ultimately save many resources during production.
The software development is aimed to provide considerable savings in terms of time, economy, and human resources, which ultimately results in faster development cycles of new drug leads.
The development started in the fall of 2019, and today we work closely with YUMAB and Abcalis to develop the best possible solution.
Today, the AI is showing great results, and we are preparing to onboard new partners and start beta testing.
If you want to be among the first to get the full potential of Biogenity's prediction software, contact us now and become one of the few early-stage partners, before we open up for beta testing. Learn more about the software, visit AB-Pred here.
You can always get the latest news on our LinkedIn about the development of the Phage display prediction software.
Thanks for reading and stay safe. We wish you, your colleagues, and your closest all the best in these difficult times.
The Biogenity Team